Aldeyra Therapeutics, Inc. (ALDX)Healthcare | Biotechnology | Lexington, United States | NasdaqCM
0.90 USD
-0.01
(-0.662%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:04 a.m. EDT
The investment case here is fundamentally broken. While the company boasts a 'strong buy' analyst recommendation and a lofty $13 price target, these figures are disconnected from the reality of a biotech firm burning through cash with negative earnings, negative free cash flow, and a deteriorating balance sheet. The market has already priced in a catastrophic failure, evidenced by the stock trading at a fraction of its 52-week high and the overwhelming presence of put options signaling a fear of further collapse. The recent insider buying, while positive, is a drop in the bucket compared to the existential risks of the business model. For a long-term investor, the lack of revenue growth and the multi-year price trajectory suggest a value trap where the low price reflects a permanent impairment of the business, not a bargain. There is no dividend to cushion the blow, and the statistical models confirm the price action is currently driven by noise rather than a predictable trend. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.070618 |
| AutoARIMA | 0.081207 |
| AutoTheta | 0.081230 |
| AutoETS | 0.081257 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 30.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.005 |
| Excess Kurtosis | 0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.379 |
| Market Cap | 54,281,712 |
| Forward P/E | -3.27 |
| Beta | 1.20 |
| Website | https://www.aldeyra.com |
As of Oct. 10, 2026, 4:04 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across nearly all expirations, with deep out-of-the-money puts showing massive volume spikes relative to calls. This indicates a 'bear put' strategy where traders are betting on further declines or hedging existing long positions against a collapse, rather than anticipating a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.83992934 |
| Address1 | 131 Hartwell Avenue |
| Address2 | Suite 320 |
| All Time High | 16.7 |
| All Time Low | 0.862 |
| Ask | 1.54 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 3,034,380 |
| Average Daily Volume3 Month | 1,174,738 |
| Average Volume | 1,174,738 |
| Average Volume10Days | 3,034,380 |
| Beta | 1.2 |
| Bid | 0.88 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.628 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8998 |
| Current Ratio | 4.907 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.91 |
| Day Low | 0.8652 |
| Debt To Equity | 0.379 |
| Display Name | Aldeyra Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -23,800,336 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.392 |
| Enterprise Value | 9,335,375 |
| Eps Current Year | -0.34 |
| Eps Forward | -0.275 |
| Eps Trailing Twelve Months | -0.38 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 339 674 6495 |
| Fifty Day Average | 1.38368 |
| Fifty Day Average Change | -0.48387998 |
| Fifty Day Average Change Percent | -0.34970513 |
| Fifty Two Week Change Percent | -83.992935 |
| Fifty Two Week High | 5.93 |
| Fifty Two Week High Change | -5.0302 |
| Fifty Two Week High Change Percent | -0.8482631 |
| Fifty Two Week Low | 0.862 |
| Fifty Two Week Low Change | 0.037800014 |
| Fifty Two Week Low Change Percent | 0.043851525 |
| Fifty Two Week Range | 0.862 - 5.93 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,399,037,400,000 |
| Float Shares | 48,948,858 |
| Forward Eps | -0.275 |
| Forward P E | -3.2719998 |
| Free Cashflow | -15,617,225 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 6 |
| Fullday Change | -0.0158 |
| Fullday Change Percent | -1.7443143 |
| Fullday Price | 0.8998 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03597 |
| Held Percent Institutions | 0.61507 |
| Implied Shares Outstanding | 60,326,421 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts. |
| Long Name | Aldeyra Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 54,281,712 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_47399863 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -23,052,740 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 80,837,404 |
| Number Of Analyst Opinions | 5 |
| Open | 0.89 |
| Operating Cashflow | -22,020,272 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Phone | 781 761 4904 |
| Previous Close | 0.9058 |
| Price Eps Current Year | -2.6464705 |
| Price Hint | 4 |
| Price To Book | 1.4328026 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.67 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.00599998 |
| Regular Market Change Percent | -0.662396 |
| Regular Market Day High | 0.91 |
| Regular Market Day Low | 0.8652 |
| Regular Market Day Range | 0.8652 - 0.91 |
| Regular Market Open | 0.89 |
| Regular Market Previous Close | 0.9058 |
| Regular Market Price | 0.8998 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 1,454,414 |
| Return On Assets | -0.22704001 |
| Return On Equity | -0.49483 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 60,326,421 |
| Shares Percent Shares Out | 0.0575 |
| Shares Short | 3,470,527 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,121,454 |
| Short Name | Aldeyra Therapeutics, Inc. |
| Short Percent Of Float | 0.0594 |
| Short Ratio | 3.7 |
| Source Interval | 15 |
| State | MA |
| Symbol | ALDX |
| Target High Price | 13.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 6.6 |
| Target Median Price | 5.0 |
| Total Cash | 45,089,784 |
| Total Cash Per Share | 0.747 |
| Total Debt | 143,447 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.550695 |
| Two Hundred Day Average Change | -1.6508949 |
| Two Hundred Day Average Change Percent | -0.64723337 |
| Type Disp | Equity |
| Volume | 1,454,414 |
| Website | https://www.aldeyra.com |
| Zip | 2,421 |